References
- Azam S, Jakaria M, Kim IS, Kim J, Haque ME, Choi DK. 2019. Regulation of Toll-Like Receptor (TLR) Signaling pathway by polyphenols in the treatment of age-linked neurodegenerative diseases: Focus on TLR4 signaling. Front Immunol. 10:1000.
- Baek SE, Park SY, Bae SS, Kim K, Lee WS, Kim CD. 2018. BLTR1 in monocytes emerges as a therapeutic target for vascular inflammation with a subsequent intimal hyperplasia in a murine wire-injured femoral artery. Front Immunol. 9:1938.
- Bergeron C, Tulic MK, Hamid Q. 2010. Airway remodelling in asthma: from benchside to clinical practice. Can Respir J. 17(4):e85–e93.
- Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A, Bianchi ME. 2003. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. Embo J. 22(20):5551–5560.
- Christian F, Smith EL, Carmody RJ. 2016. The regulation of NF-κB subunits by phosphorylation. Cells. 5(1):12.
- Dharmage SC, Perret JL, Custovic A. 2019. Epidemiology of asthma in children and adults. Front Pediatr. 7:246.
- Durrant DM, Metzger DW. 2010. Emerging roles of T helper subsets in the pathogenesis of asthma. Immunol Invest. 39(4-5):526–549.
- Fehrenbach H, Wagner C, Wegmann M. 2017. Airway remodeling in asthma: what really matters. Cell Tissue Res. 367(3):551–569.
- Galli SJ, Tsai M. 2012. IgE and mast cells in allergic disease. Nat Med. 18(5):693–704.
- Hou C, Kong J, Liang Y, Huang H, Wen H, Zheng X, Wu L, Chen Y. 2015. HMGB1 contributes to allergen-induced airway remodeling in a murine model of chronic asthma by modulating airway inflammation and activating lung fibroblasts. Cell Mol Immunol. 12(4):409–423.
- Jiang J, Hu C. 2009. Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa. Molecules. 14(5):1852–1859.
- Li CG, Zeng QZ, Chen MY, Xu LH, Zhang CC, Mai FY, Zeng CY, He XH, Ouyang DY. 2019. Evodiamine augments NLRP3 inflammasome activation and anti-bacterial responses through inducing α-tubulin acetylation. Front Pharmacol. 10:290.
- Liao JF, Chiou WF, Shen YC, Wang GJ, Chen CF. 2011. Anti-inflammatory and anti-infectious effects of Evodia rutaecarpa (Wuzhuyu) and its major bioactive components . Chin Med. 6(1):6.
- Liu T, Zhang L, Joo D, Sun SC. 2017. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2:17023.
- Moldoveanu B, Otmishi P, Jani P, Walker J, Sarmiento X, Guardiola J, Saad M, Yu J. 2009. Inflammatory mechanisms in the lung. J Inflamm Res. 2:1–11.
- National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. 2007. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda (MD): National Heart, Lung, and Blood Institute (US); Section 2, Definition, Pathophysiology and Pathogenesis of Asthma, and Natural History of Asthma.
- Qu L, Chen C, Chen Y, Li Y, Tang F, Huang H, He W, Zhang R, Shen L. 2019. High-mobility group box 1 (HMGB1) and autophagy in acute lung injury (ALI): A review. Med Sci Monit. 25:1828–1837.
- Shen P, Zhang Z, Zhu K, Cao H, Liu J, Lu X, Li Y, Jing Y, Yuan X, Fu Y, et al. 2019. Evodiamine prevents dextran sulfate sodium-induced murine experimental colitis via the regulation of NF-κB and NLRP3 inflammasome. Biomed Pharmacother. 110:786–795.
- Sprague AH, Khalil RA. 2009. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 78(6):539–552.
- Wang J, Li R, Peng Z, Hu B, Rao X, Li J. 2020. HMGB1 participates in LPS-induced acute lung injury by activating the AIM2 inflammasome in macrophages and inducing polarization of M1 macrophages via TLR2, TLR4, and RAGE/NF-κB signaling pathways. Int J Mol Med. 45(1):61–80.
- Yamauchi K, Ogasawara M. 2019. The role of histamine in the pathophysiology of asthma and the clinical efficacy of antihistamines in asthma therapy. IJMS. 20(7):1733.
- Yu H, Jin H, Gong W, Wang Z, Liang H. 2013. Pharmacological actions of multi-target-directed evodiamine. Molecules. 18(2):1826–1843.